Regulatory & Compliance

With a career spanning decades at the intersection of medical technology and finance, James Maitland has a unique vantage point on the forces shaping the industry. After a turbulent 2025 that saw medtech navigate trade wars and policy shifts, the sector proved its resilience with strong procedure

In a move that sent ripples through the tech and healthcare industries, the U.S. Food and Drug Administration unveiled a new regulatory philosophy from the unlikely stage of the Consumer Electronics Showcase, signaling a deliberate shift away from stringent oversight toward a more permissive era

The personal health information of citizens, often considered their most private and sensitive data, has become the target of a significant cyberattack, prompting a national-level investigation in New Zealand and raising serious questions about the security of digital medical records. The

From Lifeline to Legal Battle: The High Stakes of the 340B Program A critical financial support system designed to help safety-net healthcare providers serve America's most vulnerable communities recently found itself at the center of an intense legal storm. The 340B Drug Pricing Program stands as

A Lifeline Amidst a Rising Tide of Cuts In a political maneuver that simultaneously offers a lifeline and deepens a wound, the federal government has begun distributing the first round of a multi-year fund aimed at rescuing America's rural healthcare providers. This article delves into the launch

With us today is James Maitland, a leading analyst whose work focuses on the intricate intersection of U.S. healthcare policy, economics, and legislative action. As millions of Americans face the abrupt end of enhanced Affordable Care Act subsidies, we'll delve into the political gridlock in